The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...

The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...

March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...

'Paradise' season 2, episode 8 premiered March 30 on Hulu Christopher Rudolph is a contributing writer for PEOPLE. He previously covered entertainment at The Advocate, HuffPost, Logo News, MTV News ...

Renan is the Movies & TV Lead Editor for GameRant. Ren graduated Cum Laude from Lesley University in 2017 and has been focusing exclusively on his journalistic endeavors ever since. When Ren isn't ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...

Senate Republicans have for weeks been debating the use of the “talking filibuster” to guarantee the passage of the SAVE America Act in the upper chamber, after President Donald Trump called the ...

For most products, “Made in the USA” is a point of pride. For medicine, it may be about safety. After months of investigating drug manufacturing overseas, we found something rare — a company still ...

Over the last year, Sanofi has been busy reshaping itself to focus more on innovative drugs, including selling a controlling stake in its former consumer business and using those proceeds to strike a ...

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.